Feed SAVA
SA

Cassava Sciences, Inc.

SAVA · NASDAQ

$1.96 -1.76% (-$0.04)
Piotroski F-Score Weak
1/9
Valuation
-
N/A
P/E N/A
PEG N/A
EV/EBITDA N/A
Growth
-
N/A
EPS growth N/A
Book val. growth N/A
Rev. growth N/A
Profitability
-
N/A
Gross margin N/A
FCF margin N/A
Net margin N/A
Quality
-
N/A
ROIC N/A
Asset turnover N/A
ROE N/A
Debt
-
N/A
Debt/Equity N/A
Net debt/EBITDA N/A
Current ratio N/A
Stability
50 /100
Moderate
Beta -0.84x
Rev. volatility N/A
Profitable years N/A

Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe

Întreabă StockBot despre SAVA
Online

Despre companie

Cassava Sciences, Inc. (SAVA) is a biotechnology company focused on research and development of therapeutic treatments for neurodegenerative diseases. The company's primary goal is to discover innovative therapies targeting Alzheimer's disease, one of the most devastating cognitive impairing illnesses. Cassava Sciences is developing a drug known as Simufilam, which has undergone clinical trials and has shown promising results in improving cognitive functions in Alzheimer's disease patients. Investing in Cassava Sciences' stock may present an attractive opportunity for investors who closely follow advancements in neurodegenerative disease treatments and seek innovative companies with potential in the biotechnology field.

Nu este încă disponibil în limba dumneavoastră, așa că textul este în engleză.

Sector

Healthcare

Industry

Biotechnology

CEO

Richard Jon Barry

Employees

30

Headquarters

Austin

Folosim cookie-uri esențiale pentru funcționarea site-ului și cookie-uri analitice opționale pentru a măsura utilizarea. Consultați Politica de confidențialitate.